moxifloxacin has been researched along with vicriviroc in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (vicriviroc) | Trials (vicriviroc) | Recent Studies (post-2010) (vicriviroc) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 101 | 20 | 36 |
| Protein | Taxonomy | moxifloxacin (IC50) | vicriviroc (IC50) |
|---|---|---|---|
| C-C chemokine receptor type 5 | Homo sapiens (human) | 0.0016 | |
| C-C chemokine receptor type 5 | Mus musculus (house mouse) | 0.0009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caceres, M; Devinsky, O; Huddlestone, JR; Kasserra, C; Medlock, M; Morrison, R; O'Mara, E; Soni, P; Wan, Y | 1 |
1 trial(s) available for moxifloxacin and vicriviroc
| Article | Year |
|---|---|
Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Arrhythmias, Cardiac; CCR5 Receptor Antagonists; Central Nervous System; Electrocardiography; Electroencephalography; Female; Heart; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyrimidines; Ritonavir; Young Adult | 2010 |